TAKEDA-PHARMACEUTICAL
Takeda Pharmaceutical Company Limited (TSE: 4502 ) today announced that it will highlight the ixazomib clinical development program during multiple poster sessions at the upcoming 15th International Myeloma Workshop (IMW 2015 ) to be held in Rome, Italy, from September 23 to 26, 2015.
“IMW presents an important opportunity for the multiple myeloma community to come together,” said Dixie-Lee Esseltine, MD, FRCPC, Vice President, Oncology Therapeutic Area Unit, Takeda. “Ixazomib’s TOURMALINE program, which we anticipate will have over 3,000 patients when fully enrolled, is the embodiment of Takeda’s commitment to addressing the unmet needs in multiple myeloma, and now contains a pivotal trial in every major segment of this patient population. We look forward to presenting an overview of this program at IMW and engaging with our partners in the fight against multiple myeloma.”
Ixazomib is currently under review with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed and/or refractory multiple myeloma, and has been granted accelerated assessment and priority review, respectively. The regulatory submissions are based on the results of the first pre-specified interim analysis of the pivotal Phase 3 trial TOURMALINE-MM1, an international, randomized, double-blind, placebo controlled clinical trial of 722 patients designed to evaluate the superiority of once-a-week oral ixazomib plus lenalidomide and dexamethasone over placebo plus lenalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma. Additional filings in other countries are planned to begin this year. Ixazomib is the first oral proteasome inhibitor in late stage clinical development for the treatment of patients with multiple myeloma.
Ixazomib presentations at IMW 2015 are as follows:
|
Format/Timing: |
Poster Discussion; Thursday, September 24, 2015 (6:40-7:40 p.m. CEST) |
|
|
Abstract No: |
0110 |
|
|
Abstract Title: |
Four Phase 3 Studies of the Oral Proteasome Inhibitor (PI)
Ixazomib for Multiple Myeloma in the
|
|
| Authors: |
Jesus San Miguel, Philippe Moreau, Vincent Rajkumar, Antonio
Palumbo, Thierry Facon, Gareth Morgan, Robert Orlowski, |
|
| Location: | Poster Area, 1st Floor | |
|
Format/Timing: |
Poster Display; Friday, September 25, 2015 (6:40-7:40 p.m. CEST) |
|
|
Abstract No: |
0112 |
|
|
Abstract Title: |
The Current Unmet Medical Needs in the Treatment and Management of Multiple Myeloma (MM) |
|
| Authors: | Paul Richardson, Antonio Palumbo, Maria-Victoria Mateos, Helgi van de Velde, Tomas Skacel, Sagar Lonial | |
| Location: | Poster Area, 1st Floor | |
|
Format/Timing: |
Poster Discussion; Thursday, September 24, 2015 (6:40-7:40 p.m. CEST) |
|
|
Abstract No: |
0167 |
|
|
Abstract Title: |
Phase 3 Study of the Oral Proteasome Inhibitor Ixazomib for Relapsed/Refractory AL Amyloidosis: TOURMALINE-AL1 |
|
| Authors: | Giampaolo Merlini, Angela Dispenzieri, Deborah Berg, Douglas V. Faller, Ai-Min Hui, Raymond L. Comenzo | |
| Location: | Poster Area, 1st Floor | |
|
Format/Timing: |
Poster Discussion; Friday, September 25, 2015 (6:40 – 7:40 p.m. CEST) |
|
|
Abstract No: |
0177 |
|
|
Abstract Title: |
Safety Profile of Oral Ixazomib: Experience from 761 Patients Across 14 Phase 1 or Phase 1/2 Clinical Studies |
|
| Authors: | Sagar Lonial, Kathleen Colson, R. Donald Harvey, Shaji Kumar, Ai-Min Hui, Guohui Liu, Deborah Berg, Paul Richardson | |
| Location: | Poster Area, 1st Floor | |
About Ixazomib and the TOURMALINE Trials
Ixazomib is an
investigational oral proteasome inhibitor which is being studied in
multiple myeloma, systemic light-chain (AL) amyloidosis, and other
malignancies. Ixazomib was granted orphan drug designation in multiple
myeloma in both the United States and Europe in 2011 and for AL
amyloidosis in both the U.S. and Europe in 2012. Ixazomib received
Breakthrough Therapy status by the U.S. FDA for relapsed or refractory
AL amyloidosis in 2014. It is also the first oral proteasome inhibitor
to enter Phase 3 clinical trials.
Ixazomib’s clinical development program further reinforces Takeda’s ongoing commitment to developing innovative therapies for people living with multiple myeloma worldwide and the healthcare professionals who treat them. Five global Phase 3 trials are ongoing:
- TOURMALINE-MM1, investigating ixazomib vs. placebo, in combination with lenalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
- TOURMALINE-MM2, investigating ixazomib vs. placebo, in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
- TOURMALINE-MM3, investigating ixazomib vs. placebo as maintenance therapy in patients with newly diagnosed multiple myeloma following induction therapy and autologous stem cell transplant (ASCT)
- TOURMALINE-MM4, investigating ixazomib vs. placebo as maintenance therapy in patients with newly diagnosed multiple myeloma who have not undergone ASCT
- TOURMALINE-AL1, investigating ixazomib plus dexamethasone vs. physician choice of selected regimens in patients with relapsed or refractory AL amyloidosis
For additional information on the ongoing Phase 3 studies please visit www.clinicaltrials.gov .
About Multiple Myeloma
Multiple myeloma is a cancer of the
plasma cells, which are found in the bone marrow. In multiple myeloma, a
group of plasma cells, or myeloma cells, becomes cancerous and
multiplies, increasing the number of plasma cells to a higher than
normal level. Because plasma cells circulate widely in the body, they
have the potential to affect many bones in the body, possibly resulting
in compression fractures, lytic bone lesions and related pain. Multiple
myeloma can cause a number of serious health problems affecting the
bones, immune system, kidneys and red blood cell count, with some of the
more common symptoms including bone pain and fatigue, a symptom of
anemia. Multiple myeloma is a rare form of cancer with approximately
39,000 new cases in the EU and 114,000 new cases globally per year.
About Takeda Oncology
Takeda Oncology is the brand for the
global oncology business unit of Takeda Pharmaceutical Company Limited.
Takeda aspires to cure cancer by delivering novel medicines to meet the
unique and urgent needs of people living with cancer, their loved ones
and the health care providers who support them around the world. Takeda
is the 11th
largest global oncology company with a portfolio
of paradigm-changing therapies and an extensive pipeline of
investigational products that have the potential to significantly
improve patient outcomes across a number of cancers. By combining the
power of leading scientific minds with our agile and entrepreneurial
spirit and the vast resources of a global pharmaceutical company, Takeda
Oncology is finding new and innovative ways to improve the treatment of
cancer. Additional information about Takeda Oncology is available
through its website, www.takedaoncology.com
.
About Takeda
Located in Osaka, Japan, Takeda (TSE:
4502)
is a research-based global company with its main focus on
pharmaceuticals. As the largest pharmaceutical company in Japan and one
of the global leaders of the industry, Takeda is committed to strive
towards better health for people worldwide through leading innovation in
medicine.
Additional information about Takeda is available through its corporate website, www.takeda.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20150921006502/en/
Contact:
Takeda Pharmaceutical Company Limited
Japanese Media
Tsuyoshi
Tada, +81 (0) 3-3278-2417
tsuyoshi.tada@takeda.com
or
European
Media
Kate Burd, +44 7974 151510
kate.burd@takeda.com
or
Media
outside Japan/EU
Elizabeth Pingpank, +1 617-444-1495
elizabeth.pingpank@takeda.com
or
Amy
Atwood, +1 617-444-2147
amy.atwood@takeda.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
European DataWarehouse Opens Bangalore Office20.5.2025 09:04:00 CEST | Press release
European DataWarehouse (EDW), Europe’s first securitisation repository, today announced the opening of a new office in Bangalore, India. This strategic expansion underscores EDW’s continued commitment to technological innovation and excellence in client service across global markets. The Bangalore office will serve as a center for IT operations, software development, and support for EDW’s flagship platforms, EDITOR and EDVANCE. It will also enable round-the-clock service for clients operating in non-European time zones and bring previously outsourced IT services in-house—enhancing security, responsiveness, and development agility. The new office will be led by Gopala Sankaran, Chief Technology Officer at European DataWarehouse, who joined the company in 2014 and brings extensive expertise in global tech strategy and development. Dr. Christian Thun, CEO of European DataWarehouse, commented: “Establishing a presence in India is an important and exciting step for EDW. Bangalore is home to
ActiveViam’s Atoti Powers SEB’s New P&L Sentinel for Streamlined Trading Desk Oversight20.5.2025 09:00:00 CEST | Press release
ActiveViam, a global provider of advanced data analytics and decision-making solutions for the Financial Services industry, announced today that SEB AB, the leading Nordic corporate bank, has implemented and rolled out Atoti, ActiveViam's flagship product, as their P&L reporting solution. Replacing a previous technology that was heavily based on spreadsheets and ad-hoc procedures, Atoti is now being used to investigate and report Actual P&L, create adjustments, and perform sign-off on aggregated P&L figures. The application called P&L Sentinel supports P&L Control and fifteen trading desks covering all traded assets of SEB. Atoti's multidimensional cubes together with its distributed data architecture, allows SEB to have on-the-fly access from the top of house to the most granular trade details with access to historical data within forty business days, as well as aggregated historical data by portfolio supporting MTD, QTD, and YTD calculations. Atoti Sign Off, a module in the Atoti pro
2025 Thales Data Threat Report Reveals Nearly 70% of Organizations Identify AI’s Fast-Moving Ecosystem as Top GenAI-Related Security Risk20.5.2025 09:00:00 CEST | Press release
73% are investing in AI-specific security tools with either new or existing budgets. Malware remains top attack type since 2021; phishing rises to second, ransomware drops to third. 60% identified future decryption of today’s data and future encryption compromise as major concerns among quantum computing security threats. Thales today announced the release of the 2025 Thales Data Threat Report, its annual report on the latest data security threats, trends, and emerging topics based on a survey conducted by S&P Global Market Intelligence 451 Research of more than 3,100 IT and security professionals in 20 countries across 15 industries. This year’s report found that nearly 70% of organizations view the rapid pace of AI development1 —particularly in generative AI—as the leading security concern related to its adoption, followed by lack of integrity (64%) and trustworthiness (57%). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20
IQM to Deliver World-leading 300-qubit Quantum Computer to Finland20.5.2025 08:45:00 CEST | Press release
IQM will deliver two IQM Radiance quantum computers to VTT in Finland: first a 150-qubit computer in 2026 and a 300-qubit computer in 2027. The 300-qubit system is powered by two superconducting 150-qubit quantum processors. The quantum computers will be specifically designed to serve as testbeds for quantum error correction (QEC) to enable research and development for fault-tolerant quantum computers. The two quantum computers will be integrated with the Finnish HPC infrastructure. IQM Quantum Computers, a global leader in superconducting quantum computers, announced today the signing of an agreement with VTT Technical Research Centre in Finland to deliver a 150-qubit and a 300-qubit quantum computer. The systems will be delivered in 2026 and 2027 and integrated with the Finnish HPC infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250519294177/en/ IQM Radiance Quantum Computer The 300-qubit quantum computer is
Tecnotree Recognized in Gartner® Market Guide for CSP B2B Digital Marketplace Solutions20.5.2025 08:12:00 CEST | Press release
Tecnotree, a global digital platform and services leader for AI-enabled 5G and cloud-native technologies, has been named a Representative Vendor in the 2025 Gartner® Market Guide for CSP B2B Digital Marketplace Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250519187602/en/ Tecnotree Recognized in Gartner® Market Guide for CSP B2B Digital Marketplace Solutions The report highlights the strategic role of digital marketplaces in helping communications service providers (CSPs) diversify revenue streams, strengthen enterprise relationships, and lead ecosystem-driven innovation. According to Gartner, “By 2028, 60% of Tier 1 CSPs will utilize digital marketplaces to serve B2B customers, a substantial increase from around 25% today.” As per our understanding, this shift reflects a growing need for CSPs to evolve beyond traditional connectivity and offer integrated, value-added solutions through agile partner ecosystems.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum